Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Eomes broadens the scope of CD8 T-cell memory by inhibiting apoptosis in cells of low affinity.

Kavazović I, Han H, Balzaretti G, Slinger E, Lemmermann NAW, Ten Brinke A, Merkler D, Koster J, Bryceson YT, de Vries N, Jonjić S, Klarenbeek PL, Polić B, Eldering E, Wensveen FM.

PLoS Biol. 2020 Mar 17;18(3):e3000648. doi: 10.1371/journal.pbio.3000648. eCollection 2020 Mar.

2.

Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling.

Hofland T, Endstra S, Gomes CKP, de Boer R, de Weerdt I, Bobkov V, Riedl JA, Heukers R, Smit MJ, Eldering E, Levin MD, Kater AP, Tonino SH.

Hemasphere. 2019 Oct 30;3(6):e308. doi: 10.1097/HS9.0000000000000308. eCollection 2019 Dec.

3.

Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study.

Leeksma AC, Baliakas P, Moysiadis T, Puiggros A, Plevova K, van der Kevie-Kersemaekers AM, Posthuma H, Rodriguez-Vicente AE, Tran AN, Barbany G, Mansouri L, Gunnarsson R, Parker H, van den Berg E, Bellido M, Davis Z, Wall M, Scarpelli I, Österborg A, Hansson L, Jarosova M, Ghia P, Poddighe P, Espinet B, Pospisilova S, Tam C, Ysebaert L, Nguyen-Khac F, Oscier D, Haferlach C, Schoumans J, Stevens-Kroef M, Eldering E, Stamatopoulos K, Rosenquist R, Strefford JC, Mellink C, Kater AP.

Haematologica. 2020 Jan 23. pii: haematol.2019.239947. doi: 10.3324/haematol.2019.239947. [Epub ahead of print]

4.

Overexpression of SH2-Containing Inositol Phosphatase Contributes to Chronic Lymphocytic Leukemia Survival.

Pal Singh S, de Bruijn MJW, Velaso Gago da Graça C, Corneth OBJ, Rip J, Stadhouders R, Meijers RWJ, Schurmans S, Kerr WG, Ter Burg J, Eldering E, Langerak AW, Pillai SY, Hendriks RW.

J Immunol. 2020 Jan 15;204(2):360-374. doi: 10.4049/jimmunol.1900153. Epub 2019 Dec 13.

PMID:
31836657
5.

Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.

Hofland T, de Weerdt I, Ter Burg H, de Boer R, Tannheimer S, Tonino SH, Kater AP, Eldering E.

J Immunol. 2019 Oct 15;203(8):2100-2109. doi: 10.4049/jimmunol.1900321. Epub 2019 Sep 11.

PMID:
31511358
6.

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.

de Weerdt I, Hofland T, de Boer R, Dobber JA, Dubois J, van Nieuwenhuize D, Mobasher M, de Boer F, Hoogendoorn M, Velders GA, van der Klift M, Remmerswaal EBM, Bemelman FJ, Niemann CU, Kersting S, Levin MD, Eldering E, Tonino SH, Kater AP.

Blood Adv. 2019 Sep 10;3(17):2642-2652. doi: 10.1182/bloodadvances.2019000360.

7.

Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia.

Hofland T, Eldering E, Kater AP, Tonino SH.

Int J Mol Sci. 2019 Sep 3;20(17). pii: E4315. doi: 10.3390/ijms20174315. Review.

8.

The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.

Bahjat M, de Wilde G, van Dam T, Maas C, Bloedjes T, Bende RJ, van Noesel CJM, Luijks DM, Eldering E, Kersten MJ, Guikema JEJ.

Cell Cycle. 2019 Sep;18(18):2307-2322. doi: 10.1080/15384101.2019.1646068. Epub 2019 Jul 26.

9.

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy.

van Bruggen JAC, Martens AWJ, Fraietta JA, Hofland T, Tonino SH, Eldering E, Levin MD, Siska PJ, Endstra S, Rathmell JC, June CH, Porter DL, Melenhorst JJ, Kater AP, van der Windt GJW.

Blood. 2019 Jul 4;134(1):44-58. doi: 10.1182/blood.2018885863. Epub 2019 May 10.

PMID:
31076448
10.

Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.

de Weerdt I, Hofland T, Lameris R, Endstra S, Jongejan A, Moerland PD, de Bruin RCG, Remmerswaal EBM, Ten Berge IJM, Liu N, van der Stelt M, Faber LM, Levin MD, Eldering E, Tonino SH, de Gruijl TD, van der Vliet HJ, Kater AP.

Blood. 2018 Nov 22;132(21):2260-2272. doi: 10.1182/blood-2017-12-822569. Epub 2018 Sep 13. Erratum in: Blood. 2019 Oct 10;134(15):1271-1272.

PMID:
30213872
11.

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP.

Leukemia. 2019 Feb;33(2):390-402. doi: 10.1038/s41375-018-0215-9. Epub 2018 Jul 23.

12.

CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis.

van Attekum MHA, van Bruggen JAC, Slinger E, Lebre MC, Reinen E, Kersting S, Eldering E, Kater AP.

Haematologica. 2017 Dec;102(12):2069-2076. doi: 10.3324/haematol.2016.157206. Epub 2017 Sep 29.

13.

Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk.

van Attekum MH, Eldering E, Kater AP.

Haematologica. 2017 Sep;102(9):1469-1476. doi: 10.3324/haematol.2016.142679. Epub 2017 Aug 3. Review.

14.

Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer.

Guikema JE, Amiot M, Eldering E.

Expert Opin Ther Targets. 2017 Aug;21(8):767-779. doi: 10.1080/14728222.2017.1349754. Epub 2017 Jul 18. Review.

PMID:
28670929
15.

Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.

Slinger E, Thijssen R, Kater AP, Eldering E.

Leukemia. 2017 Dec;31(12):2601-2607. doi: 10.1038/leu.2017.129. Epub 2017 May 2.

PMID:
28462919
16.

Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia.

van Attekum MHA, Terpstra S, Slinger E, von Lindern M, Moerland PD, Jongejan A, Kater AP, Eldering E.

Oncogene. 2017 Jun 29;36(26):3651-3660. doi: 10.1038/onc.2016.515. Epub 2017 Feb 13.

17.

Erratum: Antigen-affinity controls pre-germinal center B cell selection by promoting Mcl-1 induction through BAFF receptor signaling.

Wensveen FM, Slinger E, van Attekum MH, Brink R, Eldering E.

Sci Rep. 2017 Jan 12;7:39366. doi: 10.1038/srep39366. No abstract available.

18.

Antigen-affinity controls pre-germinal center B cell selection by promoting Mcl-1 induction through BAFF receptor signaling.

Wensveen FM, Slinger E, van Attekum MH, Brink R, Eldering E.

Sci Rep. 2016 Oct 20;6:35673. doi: 10.1038/srep35673. Erratum in: Sci Rep. 2017 Jan 12;7:39366.

19.

Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling.

Peperzak V, Slinger E, Ter Burg J, Eldering E.

Cell Death Differ. 2017 Jan;24(1):111-119. doi: 10.1038/cdd.2016.105. Epub 2016 Sep 30.

20.

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MH, Eldering E, Kersten MJ, Kater AP.

Leukemia. 2016 Sep;30(9):1963. doi: 10.1038/leu.2016.184. No abstract available.

PMID:
27600169
21.

Macrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling.

van Attekum M, Terpstra S, Reinen E, Kater AP, Eldering E.

Cell Death Discov. 2016 Mar 21;2:16020. doi: 10.1038/cddiscovery.2016.20. eCollection 2016.

22.

Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA.

Slinger E, Wensveen FM, Guikema JE, Kater AP, Eldering E.

Haematologica. 2016 Sep;101(9):e374-7. doi: 10.3324/haematol.2016.142323. Epub 2016 Jun 13. No abstract available.

23.

The APRIL paradox in normal versus malignant B cell biology.

van Attekum MH, Kater AP, Eldering E.

Cell Death Dis. 2016 Jun 23;7(6):e2276. doi: 10.1038/cddis.2016.183. No abstract available.

24.

Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.

Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP.

Blood. 2016 Jul 28;128(4):574-83. doi: 10.1182/blood-2016-02-700328. Epub 2016 May 27.

PMID:
27235137
25.

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MH, Eldering E, Kersten MJ, Kater AP.

Leukemia. 2016 Feb;30(2):337-45. doi: 10.1038/leu.2015.241. Epub 2015 Sep 4. Erratum in: Leukemia. 2016 Sep;30(9):1963.

PMID:
26338274
26.

Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.

te Raa GD, Moerland PD, Leeksma AC, Derks IA, Yigittop H, Laddach N, Loden-van Straaten M, Navrkalova V, Trbusek M, Luijks DM, Zenz T, Skowronska A, Hoogendoorn M, Stankovic T, van Oers MH, Eldering E, Kater AP.

Cell Death Dis. 2015 Aug 6;6:e1852. doi: 10.1038/cddis.2015.223.

27.

Blimp-1 homolog Hobit identifies effector-type lymphocytes in humans.

Vieira Braga FA, Hertoghs KM, Kragten NA, Doody GM, Barnes NA, Remmerswaal EB, Hsiao CC, Moerland PD, Wouters D, Derks IA, van Stijn A, Demkes M, Hamann J, Eldering E, Nolte MA, Tooze RM, ten Berge IJ, van Gisbergen KP, van Lier RA.

Eur J Immunol. 2015 Oct;45(10):2945-58. doi: 10.1002/eji.201545650. Epub 2015 Sep 7.

28.

Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.

Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, Kater AP, Eldering E.

Haematologica. 2015 Aug;100(8):e302-6. doi: 10.3324/haematol.2015.124560. Epub 2015 May 8. No abstract available.

29.

Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.

Tonino SH, Mulkens CE, van Laar J, Derks IA, Suo G, Croon-de Boer F, van Oers MH, Eldering E, Wang JY, Kater AP.

Leuk Lymphoma. 2015;56(8):2439-47. doi: 10.3109/10428194.2014.996751. Epub 2015 Jan 21.

30.

The impact of SF3B1 mutations in CLL on the DNA-damage response.

Te Raa GD, Derks IA, Navrkalova V, Skowronska A, Moerland PD, van Laar J, Oldreive C, Monsuur H, Trbusek M, Malcikova J, Lodén M, Geisler CH, Hüllein J, Jethwa A, Zenz T, Pospisilova S, Stankovic T, van Oers MH, Kater AP, Eldering E.

Leukemia. 2015 May;29(5):1133-42. doi: 10.1038/leu.2014.318. Epub 2014 Nov 5.

PMID:
25371178
31.

miR in CLL: more than mere markers of prognosis?

Kater AP, Eldering E.

Blood. 2014 Jul 3;124(1):2-4. doi: 10.1182/blood-2014-05-574152.

PMID:
24993874
32.

Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach.

Te Raa GD, Malčiková J, Mraz M, Trbusek M, Le Garff-Tavernier M, Merle-Béral H, Greil R, Merkel O, Pospíšilová S, Lin K, Pettitt AR, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC).

Br J Haematol. 2014 Nov;167(4):565-9. doi: 10.1111/bjh.13006. Epub 2014 Jun 30. No abstract available.

PMID:
24975017
33.

BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Spaargaren M, de Rooij MF, Kater AP, Eldering E.

Oncogene. 2015 May 7;34(19):2426-36. doi: 10.1038/onc.2014.181. Epub 2014 Jun 23. Review.

PMID:
24954503
34.

CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia.

te Raa GD, Pascutti MF, García-Vallejo JJ, Reinen E, Remmerswaal EB, ten Berge IJ, van Lier RA, Eldering E, van Oers MH, Tonino SH, Kater AP.

Blood. 2014 Jan 30;123(5):717-24. doi: 10.1182/blood-2013-08-518183. Epub 2013 Nov 18.

PMID:
24246502
35.

Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.

Kater AP, Spiering M, Liu RD, Doreen Te Raa G, Slinger E, Tonino SH, Beckers MM, Daenen S, Doorduijn JK, Lankheet NA, Luijks DM, Eldering E, van Oers MH.

Leuk Res. 2014 Jan;38(1):34-41. doi: 10.1016/j.leukres.2013.10.004. Epub 2013 Oct 28.

PMID:
24238639
36.

Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.

Lascano V, Guadagnoli M, Schot JG, Luijks DM, Guikema JE, Cameron K, Hahne M, Pals S, Slinger E, Kipps TJ, van Oers MH, Eldering E, Medema JP, Kater AP.

Blood. 2013 Dec 5;122(24):3960-3. doi: 10.1182/blood-2013-04-497693. Epub 2013 Oct 7.

37.

IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.

Pascutti MF, Jak M, Tromp JM, Derks IA, Remmerswaal EB, Thijssen R, van Attekum MH, van Bochove GG, Luijks DM, Pals ST, van Lier RA, Kater AP, van Oers MH, Eldering E.

Blood. 2013 Oct 24;122(17):3010-9. doi: 10.1182/blood-2012-11-467670. Epub 2013 Sep 6.

PMID:
24014238
38.

CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex.

Maas C, Tromp JM, van Laar J, Thijssen R, Elias JA, Malara A, Krippner-Heidenreich A, Silke J, van Oers MH, Eldering E.

Cell Death Dis. 2013 Aug 29;4:e782. doi: 10.1038/cddis.2013.305.

39.

BH3-only protein Noxa contributes to apoptotic control of stress-erythropoiesis.

Wensveen FM, Geest CR, Libregts SFWM, Derks IAM, Ekert PG, Labi V, Villunger A, Nolte MA, Eldering E.

Apoptosis. 2013 Nov;18(11):1306-1318. doi: 10.1007/s10495-013-0890-y.

40.

Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia.

te Raa GD, Malcikova J, Pospisilova S, Trbusek M, Mraz M, Garff-Tavernier ML, Merle-Béral H, Lin K, Pettitt AR, Merkel O, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC).

Leuk Lymphoma. 2013 Aug;54(8):1849-53. doi: 10.3109/10428194.2013.796058. Epub 2013 Jun 24. Review.

PMID:
23614766
41.

The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia.

de Weerdt I, Eldering E, van Oers MH, Kater AP.

Leuk Res. 2013 Jul;37(7):838-47. doi: 10.1016/j.leukres.2013.03.011. Epub 2013 Apr 15. Review.

PMID:
23597579
42.

Pro-apoptotic protein Noxa regulates memory T cell population size and protects against lethal immunopathology.

Wensveen FM, Klarenbeek PL, van Gisbergen KP, Pascutti MF, Derks IA, van Schaik BD, Ten Brinke A, de Vries N, Cekinovic D, Jonjic S, van Lier RA, Eldering E.

J Immunol. 2013 Feb 1;190(3):1180-91. doi: 10.4049/jimmunol.1202304. Epub 2012 Dec 31.

43.

Effect of oxidative stress on respiratory epithelium from children with Down syndrome.

Bruijn M, Lutter R, Eldering E, Bos AP, van Woensel JB.

Eur Respir J. 2013 Oct;42(4):1037-45. doi: 10.1183/09031936.00122812. Epub 2012 Nov 22.

44.

The fourth dimension in immunological space: how the struggle for nutrients selects high-affinity lymphocytes.

Wensveen FM, van Gisbergen KP, Eldering E.

Immunol Rev. 2012 Sep;249(1):84-103. doi: 10.1111/j.1600-065X.2012.01156.x. Review.

PMID:
22889217
45.

Viral double-stranded RNA sensors induce antiviral, pro-inflammatory, and pro-apoptotic responses in human renal tubular epithelial cells.

Heutinck KM, Rowshani AT, Kassies J, Claessen N, van Donselaar-van der Pant KA, Bemelman FJ, Eldering E, van Lier RA, Florquin S, Ten Berge IJ, Hamann J.

Kidney Int. 2012 Sep;82(6):664-75. doi: 10.1038/ki.2012.206. Epub 2012 May 30.

46.

Notch controls the magnitude of T helper cell responses by promoting cellular longevity.

Helbig C, Gentek R, Backer RA, de Souza Y, Derks IA, Eldering E, Wagner K, Jankovic D, Gridley T, Moerland PD, Flavell RA, Amsen D.

Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9041-6. doi: 10.1073/pnas.1206044109. Epub 2012 May 21.

47.

CD70-driven costimulation induces survival or Fas-mediated apoptosis of T cells depending on antigenic load.

Wensveen FM, Unger PP, Kragten NA, Derks IA, ten Brinke A, Arens R, van Lier RA, Eldering E, van Gisbergen KP.

J Immunol. 2012 May 1;188(9):4256-67. doi: 10.4049/jimmunol.1102889. Epub 2012 Mar 26.

48.

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, Pals ST, Spaargaren M.

Blood. 2012 Mar 15;119(11):2590-4. doi: 10.1182/blood-2011-11-390989. Epub 2012 Jan 25.

PMID:
22279054
49.

BH3-only protein Noxa regulates apoptosis in activated B cells and controls high-affinity antibody formation.

Wensveen FM, Derks IA, van Gisbergen KP, de Bruin AM, Meijers JC, Yigittop H, Nolte MA, Eldering E, van Lier RA.

Blood. 2012 Feb 9;119(6):1440-9. doi: 10.1182/blood-2011-09-378877. Epub 2011 Dec 5.

PMID:
22144184
50.

Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.

Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, van Oers MH, Eldering E.

Clin Cancer Res. 2012 Jan 15;18(2):487-98. doi: 10.1158/1078-0432.CCR-11-1440. Epub 2011 Nov 29.

Supplemental Content

Loading ...
Support Center